Immutep Limited

NasdaqGM:IMMP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Australia

Market Cap

USD 232.89 M

Share Price

USD 1.60

Avg Daily Volume

280,323

Change (1 day)

-0.62%

Change (1 year)

-38.22%

Change (YTD)

-26.27%

Immutep Limited Share Price on June 20, 2025: USD 1.60

Immutep Limited Share Price is USD 1.60 on June 20, 2025, a -38.22% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Immutep Limited 52-week low Share Price is USD 2.77 on June 20, 2025, which is 73.12% above the current Share Price.
Immutep Limited 52-week low Share Price is USD 1.41 on June 20, 2025, which is -11.88% below the current Share Price.
Immutep Limited average Share Price for the last 52 weeks is USD 1.99.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqGM: IMMP

Immutep Limited

CEO	Mr. Marc Voigt
IPO Date	April 19, 2012
Location	Australia
Headquarters	Australia Square
Employees	41
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.